Dalbavancin (Dalvance, Xydalba) is a semisynthetic lipoglycopeptide approved in 2014 by the US Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency for acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Grampositive isolates in adults. Although originally approved for a twodose regimen, the compound has an extended halflife (t1/2) that enables singledose therapy for ABSSSIs (Dunne et al., 2016a; Dunne et al., 2016b). Dalbavancin has potent in vitro activity against most Grampositive organisms with lower minimum inhibitory concentration (MIC) values than vancomycin and other investigational lipoglycopeptides (i.e. oritavancin, telavancin). It is also active against drugresistant pathogens of concern such as methicillinresistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), except for strains exhibiting vanA resistance.
|Original language||English (US)|
|Title of host publication||Kucers the Use of Antibiotics|
|Subtitle of host publication||A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition|
|Number of pages||13|
|Publication status||Published - Jan 1 2017|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)